Ferroptosis-centered Disease Response Information
General Information of the Disease (ID: DIS00047)
Name |
Thyroid cancer
|
||||
---|---|---|---|---|---|
ICD |
ICD-11: 2D10
|
Full List of Target(s) of This Ferroptosis-centered Disease
Phospholipid hydroperoxide glutathione peroxidase (GPX4)
In total 4 item(s) under this target | |||||
Experiment 1 Reporting the Ferroptosis-centered Disease Response by This Target | [1] | ||||
Target for Ferroptosis | Suppressor | ||||
Responsed Disease | Anaplastic thyroid cancer [ICD-11: 2D10] | ||||
Responsed Drug | Ascorbic Acid | Approved | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Ferroptosis | hsa04216 | ||||
Cell Process | Cell ferroptosis | ||||
Cell autophagy | |||||
Cell proliferation | |||||
In Vitro Model | 8505C cells | Thyroid gland anaplastic carcinoma | Homo sapiens | CVCL_1054 | |
C643 cells | Thyroid gland anaplastic carcinoma | Homo sapiens | CVCL_5969 | ||
Response regulation | Vitamin C could significantly inhibit anaplastic thyroid cancer (ATC) cells growth through ferroptosis activation, evidenced by the GPX4 inactivation, ROS accumulation and iron-dependent lipid peroxidation. | ||||
Experiment 2 Reporting the Ferroptosis-centered Disease Response by This Target | [2] | ||||
Target for Ferroptosis | Suppressor | ||||
Responsed Disease | Follicular thyroid cancer [ICD-11: 2D10] | ||||
Responsed Drug | Curcumin | Investigative | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Cell Process | Cell ferroptosis | ||||
In Vitro Model | Nthy-ori3-1 cells | Normal | Homo sapiens | CVCL_2659 | |
Nthy-ori3-1 cells | Normal | Homo sapiens | CVCL_2659 | ||
FTC 238 cells | Thyroid gland follicular carcinoma | Homo sapiens | CVCL_2447 | ||
Response regulation | Knockdown of HO-1 inhibits ferroptosis by upregulating the GPX4 expression in follicular thyroid cancer cells. We conclude that curcumin inhibits the tumorigenesis of follicular thyroid cancer via HO-1-induced activation of the ferroptosis signalling pathway. | ||||
Experiment 3 Reporting the Ferroptosis-centered Disease Response by This Target | [3] | ||||
Target for Ferroptosis | Suppressor | ||||
Responsed Disease | Thyroid cancer [ICD-11: 2D10] | ||||
Responsed Regulator | CircKIF4A (circRNA) | Suppressor | |||
Pathway Response | Glutathione metabolism | hsa00480 | |||
Cell Process | Cell ferroptosis | ||||
Cell proliferation | |||||
In Vitro Model | KAT-5 cells | Colon adenocarcinoma | Homo sapiens | CVCL_0370 | |
TPC-1 cells | Thyroid gland papillary carcinoma | Homo sapiens | CVCL_6298 | ||
In Vivo Model |
KAT-5 and TPC-1 cells (2 x 107) were subcutaneously injected into nude mice (four mice/group, 4-week-old) and treated with intratumoral injection (50 uL si-circCON, si-circKIF4A) every four days. The volume of tumors was estimated every four days according to the formula 0.5 x width2 x length. After 28 days, the tumors were weighed. Forin vivolung metastasis assay, cells (1 x 105) were injected through tail veins (four mice/group).
Click to Show/Hide
|
||||
Response regulation | circKIF4A facilitated the malignant progress of papillary thyroid tumor by sponging miR-1231 and upregulating GPX4 expression. And circKIF4A-miR-1231-GPX4 axis played a vital role in cancer proliferation and ferroptosis by competing endogenous RNAs. Therefore, targeting circKIF4A is very likely to be a potential method for treatment of papillary thyroid cancer in the future. | ||||
Experiment 4 Reporting the Ferroptosis-centered Disease Response by This Target | [3] | ||||
Target for Ferroptosis | Suppressor | ||||
Responsed Disease | Thyroid cancer [ICD-11: 2D10] | ||||
Responsed Regulator | hsa-miR-1231 (miRNA) | Driver | |||
Pathway Response | Glutathione metabolism | hsa00480 | |||
Cell Process | Cell ferroptosis | ||||
Cell proliferation | |||||
In Vitro Model | KAT-5 cells | Colon adenocarcinoma | Homo sapiens | CVCL_0370 | |
TPC-1 cells | Thyroid gland papillary carcinoma | Homo sapiens | CVCL_6298 | ||
In Vivo Model |
KAT-5 and TPC-1 cells (2 x 107) were subcutaneously injected into nude mice (four mice/group, 4-week-old) and treated with intratumoral injection (50 uL si-circCON, si-circKIF4A) every four days. The volume of tumors was estimated every four days according to the formula 0.5 x width2 x length. After 28 days, the tumors were weighed. Forin vivolung metastasis assay, cells (1 x 105) were injected through tail veins (four mice/group).
Click to Show/Hide
|
||||
Response regulation | circKIF4A facilitated the malignant progress of papillary thyroid tumor by sponging miR-1231 and upregulating GPX4 expression. And circKIF4A- miR-1231-GPX4 axis played a vital role in cancer proliferation and ferroptosis by competing endogenous RNAs. Therefore, targeting circKIF4A is very likely to be a potential method for treatment of papillary thyroid cancer in the future. | ||||
Nuclear receptor coactivator 4 (NCOA4)
In total 1 item(s) under this target | |||||
Experiment 1 Reporting the Ferroptosis-centered Disease Response by This Target | [4] | ||||
Target for Ferroptosis | Driver | ||||
Responsed Disease | Anaplastic thyroid cancer [ICD-11: 2D10] | ||||
Responsed Regulator | NAD-dependent protein deacylase sirtuin-6 (SIRT6) | Driver | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Ferroptosis | hsa04216 | ||||
Autophagy | hsa04140 | ||||
Cell Process | Cell ferroptosis | ||||
Cell autophagy | |||||
In Vitro Model | CAL62 cells | Thyroid gland anaplastic carcinoma | Homo sapiens | CVCL_1112 | |
BHT101 cells | Anaplastic thyroid carcinoma | Homo sapiens | CVCL_1085 | ||
In Vivo Model |
Six-week-old male BALB/c-nu mice were provided by Beijing Vital River Laboratory Animal Technology Co. Ltd. All mice were randomly divided into 6 equal groups (CAL62-NC-Blank, CAL62-NC-sulfasalazine, CAL62-NC-sulfasalazine + CQ; CAL62-SIRT6-Blank, CAL62-SIRT6-sulfasalazine, CAL62-SIRT6-sulfasalazine + CQ). CAL62-NC or CAL62-SIRT6 cells (5 x 106) suspended in 100 ul PBS were injected subcutaneously into the axilla of each nude mouse. After 5 days, the mice were treated with different reagents: solvent (100 ul 0.1 M NaOH and 100 ul saline), sulfasalazine (200 mg/kg, i.p., dissolved in 100 ul 0.1 M NaOH), CQ (50 mg/kg, i.p., dissolved in 100 ul saline).
Click to Show/Hide
|
||||
Response regulation | SIRT6-driven sensitivity to ferroptosis via NCOA4-dependent autophagy and proposed ferroptosis inducers as promising therapeutic agents for anaplastic thyroid cancer patients. The clinically used ferroptosis inducer sulfasalazine showed promising therapeutic effects on SIRT6-upregulated thyroid cancer cells in vivo. | ||||
Heme oxygenase 1 (HMOX1)
In total 1 item(s) under this target | ||||
Experiment 1 Reporting the Ferroptosis-centered Disease Response by This Target | [2] | |||
Target for Ferroptosis | Driver | |||
Responsed Disease | Follicular thyroid cancer [ICD-11: 2D10] | |||
Responsed Drug | Curcumin | Investigative | ||
Pathway Response | Fatty acid metabolism | hsa01212 | ||
Cell Process | Cell ferroptosis | |||
In Vitro Model | Nthy-ori3-1 cells | Normal | Homo sapiens | CVCL_2659 |
Nthy-ori3-1 cells | Normal | Homo sapiens | CVCL_2659 | |
FTC 238 cells | Thyroid gland follicular carcinoma | Homo sapiens | CVCL_2447 | |
Response regulation | Knockdown of HO-1 inhibits ferroptosis by upregulating the GPX4 expression in follicular thyroid cancer cells. We conclude that curcumin inhibits the tumorigenesis of follicular thyroid cancer via HO-1-induced activation of the ferroptosis signalling pathway. | |||
Cystine/glutamate transporter (SLC7A11)
In total 6 item(s) under this target | |||||
Experiment 1 Reporting the Ferroptosis-centered Disease Response by This Target | [5] | ||||
Target for Ferroptosis | Suppressor | ||||
Responsed Disease | Thyroid cancer [ICD-11: 2D10] | ||||
Responsed Regulator | Circ_0067934 (circRNA) | Suppressor | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Ferroptosis | hsa04216 | ||||
Apoptosis | hsa04210 | ||||
Cell Process | Cell ferroptosis | ||||
Cell apoptosis | |||||
Cell proliferation | |||||
In Vitro Model | FTC-133 cells | Thyroid gland follicular carcinoma | Homo sapiens | CVCL_1219 | |
TPC-1 cells | Thyroid gland papillary carcinoma | Homo sapiens | CVCL_6298 | ||
In Vivo Model |
BALB/c nude mice (18-20 g, 4-week-old, male) (n = 6) were purchased and applied for the tumor growth analysis of FTC133 cellsin vivo. About 1 x 106 FTC133 cells were transfected with control shRNA or circ_0067934 shRNA and were subcutaneously injected into the left fat pad of mice. After 5 days of injection, we measured tumor growth every 5 days. We sacrificed the mice after 30 days of injection. The tumor volume was calculated by (length x width2)/2. And the tumor weight was calculated at day 30.
Click to Show/Hide
|
||||
Response regulation | Circ_0067934 upregulated the expression of the ferroptosis-negative regulator SLC7A11 by sponging and inhibiting miR-545-3p in thyroid cancer cells. The overexpression of SLC7A11 or the inhibitor of miR-545-3p reversed circ_0067934 silencing-regulated thyroid cancer cell proliferation. | ||||
Experiment 2 Reporting the Ferroptosis-centered Disease Response by This Target | [5] | ||||
Target for Ferroptosis | Suppressor | ||||
Responsed Disease | Thyroid cancer [ICD-11: 2D10] | ||||
Responsed Regulator | hsa-miR-545-3p (miRNA) | Driver | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Ferroptosis | hsa04216 | ||||
Apoptosis | hsa04210 | ||||
Cell Process | Cell ferroptosis | ||||
Cell apoptosis | |||||
Cell proliferation | |||||
In Vitro Model | FTC-133 cells | Thyroid gland follicular carcinoma | Homo sapiens | CVCL_1219 | |
TPC-1 cells | Thyroid gland papillary carcinoma | Homo sapiens | CVCL_6298 | ||
In Vivo Model |
BALB/c nude mice (18-20 g, 4-week-old, male) (n = 6) were purchased and applied for the tumor growth analysis of FTC133 cellsin vivo. About 1 x 106 FTC133 cells were transfected with control shRNA or circ_0067934 shRNA and were subcutaneously injected into the left fat pad of mice. After 5 days of injection, we measured tumor growth every 5 days. We sacrificed the mice after 30 days of injection. The tumor volume was calculated by (length x width2)/2. And the tumor weight was calculated at day 30.
Click to Show/Hide
|
||||
Response regulation | Circ_0067934 upregulated the expression of the ferroptosis-negative regulator SLC7A11 by sponging and inhibiting miR-545-3p in thyroid cancer cells. The overexpression of SLC7A11 or the inhibitor of miR-545-3p reversed circ_0067934 silencing-regulated thyroid cancer cell proliferation. | ||||
Experiment 3 Reporting the Ferroptosis-centered Disease Response by This Target | [6] | ||||
Target for Ferroptosis | Suppressor | ||||
Responsed Disease | Papillary thyroid cancer [ICD-11: 2D10] | ||||
Responsed Regulator | CERS6-AS1 (IncRNA) | Suppressor | |||
Pathway Response | Ferroptosis | hsa04216 | |||
Cell Process | Cell ferroptosis | ||||
Cell proliferation | |||||
In Vitro Model | Nthy-ori3-1 cells | Normal | Homo sapiens | CVCL_2659 | |
IHH-4 cells | Thyroid gland papillary carcinoma | Homo sapiens | CVCL_2960 | ||
BCPAP cells | Thyroid carcinoma | Homo sapiens | CVCL_0153 | ||
KTC-1 cells | Thyroid carcinoma | Homo sapiens | CVCL_6300 | ||
TPC-1 cells | Thyroid gland papillary carcinoma | Homo sapiens | CVCL_6298 | ||
In Vivo Model |
Animal experiments were approved by ethics committee of Wuzhou Red Cross Hospital. The TPC-1 cells transfected with sh-CERS6-AS1 or sh-NC were made into cell suspension (2 x 106/ml) with PBS. Then nude mice were randomly divided into sh-CERS6-AS1 group (n = 6) and sh-NC group (n = 6). The mice were subcutaneously inoculated with 200 ul corresponding cell suspension respectively, and then the weight and tumor volume of mice were recorded every other week. After 5 weeks, pentobarbital sodium (120 mg/kg) were intraperitoneally injected to make nude mice euthanasia, and then the tumors were stripped and weighed. Subsequently, immunohistochemistry and RT-PCR were performed.
Click to Show/Hide
|
||||
Response regulation | Silencing CERS6-AS1 suppressed cell viability and increased ferroptosis in papillary thyroid cancer. LASP1 was modulated by CERS6-AS1 through sponging miR-497-5p. The expression of Ki67, PCNA, GPX4, and SLC7A11 was inhibited by si- CERS6-AS1 transfection. | ||||
Experiment 4 Reporting the Ferroptosis-centered Disease Response by This Target | [6] | ||||
Target for Ferroptosis | Suppressor | ||||
Responsed Disease | Papillary thyroid cancer [ICD-11: 2D10] | ||||
Responsed Regulator | LIM and SH3 domain protein 1 (LASP1) | Suppressor | |||
Pathway Response | Ferroptosis | hsa04216 | |||
Cell Process | Cell ferroptosis | ||||
Cell proliferation | |||||
In Vitro Model | Nthy-ori3-1 cells | Normal | Homo sapiens | CVCL_2659 | |
IHH-4 cells | Thyroid gland papillary carcinoma | Homo sapiens | CVCL_2960 | ||
BCPAP cells | Thyroid carcinoma | Homo sapiens | CVCL_0153 | ||
KTC-1 cells | Thyroid carcinoma | Homo sapiens | CVCL_6300 | ||
TPC-1 cells | Thyroid gland papillary carcinoma | Homo sapiens | CVCL_6298 | ||
In Vivo Model |
Animal experiments were approved by ethics committee of Wuzhou Red Cross Hospital. The TPC-1 cells transfected with sh-CERS6-AS1 or sh-NC were made into cell suspension (2 x 106/ml) with PBS. Then nude mice were randomly divided into sh-CERS6-AS1 group (n = 6) and sh-NC group (n = 6). The mice were subcutaneously inoculated with 200 ul corresponding cell suspension respectively, and then the weight and tumor volume of mice were recorded every other week. After 5 weeks, pentobarbital sodium (120 mg/kg) were intraperitoneally injected to make nude mice euthanasia, and then the tumors were stripped and weighed. Subsequently, immunohistochemistry and RT-PCR were performed.
Click to Show/Hide
|
||||
Response regulation | Silencing CERS6-AS1 suppressed cell viability and increased ferroptosis in papillary thyroid cancer. LASP1 was modulated by CERS6-AS1 through sponging miR-497-5p. The expression of Ki67, PCNA, GPX4, and SLC7A11 was inhibited by si-CERS6-AS1 transfection. | ||||
Experiment 5 Reporting the Ferroptosis-centered Disease Response by This Target | [6] | ||||
Target for Ferroptosis | Suppressor | ||||
Responsed Disease | Papillary thyroid cancer [ICD-11: 2D10] | ||||
Responsed Regulator | hsa-miR-497-5p (miRNA) | Driver | |||
Pathway Response | Ferroptosis | hsa04216 | |||
Cell Process | Cell ferroptosis | ||||
Cell proliferation | |||||
In Vitro Model | Nthy-ori3-1 cells | Normal | Homo sapiens | CVCL_2659 | |
IHH-4 cells | Thyroid gland papillary carcinoma | Homo sapiens | CVCL_2960 | ||
BCPAP cells | Thyroid carcinoma | Homo sapiens | CVCL_0153 | ||
KTC-1 cells | Thyroid carcinoma | Homo sapiens | CVCL_6300 | ||
TPC-1 cells | Thyroid gland papillary carcinoma | Homo sapiens | CVCL_6298 | ||
In Vivo Model |
Animal experiments were approved by ethics committee of Wuzhou Red Cross Hospital. The TPC-1 cells transfected with sh-CERS6-AS1 or sh-NC were made into cell suspension (2 x 106/ml) with PBS. Then nude mice were randomly divided into sh-CERS6-AS1 group (n = 6) and sh-NC group (n = 6). The mice were subcutaneously inoculated with 200 ul corresponding cell suspension respectively, and then the weight and tumor volume of mice were recorded every other week. After 5 weeks, pentobarbital sodium (120 mg/kg) were intraperitoneally injected to make nude mice euthanasia, and then the tumors were stripped and weighed. Subsequently, immunohistochemistry and RT-PCR were performed.
Click to Show/Hide
|
||||
Response regulation | Silencing CERS6-AS1 suppressed cell viability and increased ferroptosis in papillary thyroid cancer. LASP1 was modulated by CERS6-AS1 through sponging miR-497-5p. The expression of Ki67, PCNA, GPX4, and SLC7A11 was inhibited by si-CERS6-AS1 transfection. | ||||
Experiment 6 Reporting the Ferroptosis-centered Disease Response by This Target | [7] | ||||
Target for Ferroptosis | Suppressor | ||||
Responsed Disease | Papillary thyroid cancer [ICD-11: 2D10] | ||||
Responsed Regulator | ETS translocation variant 4 (ETV4) | Suppressor | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Ferroptosis | hsa04216 | ||||
Cell Process | Cell ferroptosis | ||||
Cell proliferation | |||||
Cell cycle | |||||
In Vitro Model | TPC-1 cells | Thyroid gland papillary carcinoma | Homo sapiens | CVCL_6298 | |
IHH-4 cells | Thyroid gland papillary carcinoma | Homo sapiens | CVCL_2960 | ||
Nthy-ori3-1 cells | Normal | Homo sapiens | CVCL_2659 | ||
In Vivo Model |
Six-week-old BALB/c female nude mice (HFK Bioscience, Beijing, China) were used to perform experimentsin vivo. One hundred forty-four mice were randomly divided into four groups (36 mice in each group). TPC-1 cells were stably transfected with NC shRNA or ETV4-shRNA, and GLAG-66 cells were stably transfected with ETV4-OE or Vector. 5 x 106 cells were injected subcutaneously into the right armpit in mice. After 7 days, the diameter of tumors was measured every 3 days to calculate the tumor volume.
Click to Show/Hide
|
||||
Response regulation | The downregulation of ETV4 repressed the tumor development through the low expression of SLC7A11, and the ETV4 overexpression obtained the contrary effects. Overall, knockdown of ETV4 suppressed the papillary thyroid cancer progression by promoting ferroptosis upon SLC7A11 downregulation. | ||||
References